SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Artemis Therapeutics, Inc. – ‘S-1’ on 9/21/22 – ‘EX-101.CAL’

On:  Wednesday, 9/21/22, at 4:03pm ET   ·   Accession #:  1178913-22-3487   ·   File #:  333-267534

Previous ‘S-1’:  None   ·   Next:  ‘S-1/A’ on 11/21/22   ·   Latest:  ‘S-1/A’ on 1/4/23   ·   5 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/21/22  Artemis Therapeutics, Inc.        S-1                   56:5.7M                                   Z-K Global Ltd./FA

Registration Statement (General Form)   —   Form S-1   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   1.89M 
 2: EX-10.8     Form of Indemnification Agreement                   HTML     54K 
 3: EX-23.1     Consent of Expert or Counsel -- exhibit_23-1        HTML     16K 
 4: EX-FILING FEES  Calculation of Filing Fee Tables                HTML     24K 
10: R1          Document and Entity Information                     HTML     29K 
11: R2          Interim Condensed Consolidated Balance Sheets       HTML    135K 
12: R3          Interim Condensed Consolidated Balance Sheets       HTML     40K 
                (Parenthetical)                                                  
13: R4          Interim Condensed Consolidated Statements of        HTML     85K 
                Comprehensive Loss (Unaudited)                                   
14: R5          Interim Condensed Statements of Stockholders'       HTML     85K 
                Equity (Unaudited)                                               
15: R6          Interim Condensed Consolidated Statement of Cash    HTML     86K 
                Flows (Unaudited)                                                
16: R7          Description of Business and General                 HTML     31K 
17: R8          Summary of Significant Accounting Policies          HTML     56K 
18: R9          Inventories                                         HTML     34K 
19: R10         Commitments and Contingencies                       HTML     22K 
20: R11         Property and Equipment, Net                         HTML     36K 
21: R12         Intangibles, Net                                    HTML     28K 
22: R13         Leases                                              HTML     71K 
23: R14         Stockholders' Equity                                HTML     36K 
24: R15         Related Party Balances and Transactions             HTML     55K 
25: R16         Tax on Income                                       HTML     37K 
26: R17         Subsequent Events                                   HTML     21K 
27: R18         Summary of Significant Accounting Policies          HTML     96K 
                (Policies)                                                       
28: R19         Summary of Significant Accounting Policies          HTML     21K 
                (Tables)                                                         
29: R20         Inventories (Tables)                                HTML     33K 
30: R21         Leases (Tables)                                     HTML     67K 
31: R22         Property and Equipment, Net (Tables)                HTML     34K 
32: R23         Intangibles, Net (Tables)                           HTML     27K 
33: R24         Tax on Income (Tables)                              HTML     28K 
34: R25         Related Party Balances and Transactions (Tables)    HTML     46K 
35: R26         Description of Business and General (Narrative)     HTML     43K 
                (Details)                                                        
36: R27         Summary of Significant Accounting Policies          HTML     24K 
                (Details)                                                        
37: R28         Inventories (Details)                               HTML     23K 
38: R29         Property and Equipment, Net (Details)               HTML     30K 
39: R30         Property and Equipment, Net (Narrative) (Details)   HTML     19K 
40: R31         Intangibles, Net (Details)                          HTML     27K 
41: R32         Commitments and Contingencies (Narrative)           HTML     24K 
                (Details)                                                        
42: R33         Leases (Details)                                    HTML     21K 
43: R34         Leases (Details 1)                                  HTML     27K 
44: R35         Leases (Details 2)                                  HTML     29K 
45: R36         Stockholders' Equity (Narrative) (Details)          HTML     64K 
46: R37         Related Party Balances and Transactions (Details)   HTML     20K 
47: R38         Related Party Balances and Transactions (Details    HTML     24K 
                1)                                                               
48: R39         Related Party Balances and Transactions             HTML     27K 
                (Narrative) (Details)                                            
49: R40         Tax on Income (Schedule of Deferred Income Taxes)   HTML     25K 
                (Details)                                                        
50: R41         Tax on Income (Narrative) (Details)                 HTML     28K 
51: R42         Subsequent Events (Narrative) (Details)             HTML     35K 
54: XML         IDEA XML File -- Filing Summary                      XML     98K 
52: XML         XBRL Instance -- zk2228396_htm                       XML   1.01M 
53: EXCEL       IDEA Workbook of Financial Reports                  XLSX     89K 
 6: EX-101.CAL  XBRL Calculations -- atms-20220630_cal               XML     95K 
 7: EX-101.DEF  XBRL Definitions -- atms-20220630_def                XML    261K 
 8: EX-101.LAB  XBRL Labels -- atms-20220630_lab                     XML   1.13M 
 9: EX-101.PRE  XBRL Presentations -- atms-20220630_pre              XML    475K 
 5: EX-101.SCH  XBRL Schema -- atms-20220630                         XSD    121K 
55: JSON        XBRL Instance as JSON Data -- MetaLinks              261±   358K 
56: ZIP         XBRL Zipped Folder -- 0001178913-22-003487-xbrl      Zip    460K

‘EX-101.CAL’   —   XBRL Calculations — atms-20220630_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"> <!-- INTEGIX by Ez-XBRL -->
<roleRef xlink:type="simple" xlink:href="atms-20220630.xsd#inks-ccsoo" roleURI="http://www.artemistherapeutics.com/role/inks-ccsoo"/>
<roleRef xlink:type="simple" xlink:href="atms-20220630.xsd#InterimCondensedConsolidatedBalanceSheets" roleURI="http://www.artemistherapeutics.com/role/InterimCondensedConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="atms-20220630.xsd#InterimCondensedConsolidatedStatementOfCashFlows" roleURI="http://www.artemistherapeutics.com/role/InterimCondensedConsolidatedStatementOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="atms-20220630.xsd#INVENTORIESDetails" roleURI="http://www.artemistherapeutics.com/role/INVENTORIESDetails"/>
<roleRef xlink:type="simple" xlink:href="atms-20220630.xsd#LEASESDetails" roleURI="http://www.artemistherapeutics.com/role/LEASESDetails"/>
<roleRef xlink:type="simple" xlink:href="atms-20220630.xsd#LEASESDetails2" roleURI="http://www.artemistherapeutics.com/role/LEASESDetails2"/>
<roleRef xlink:type="simple" xlink:href="atms-20220630.xsd#IncomeTaxScheduleOfDeferredIncomeTaxesDetails" roleURI="http://www.artemistherapeutics.com/role/IncomeTaxScheduleOfDeferredIncomeTaxesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.artemistherapeutics.com/role/inks-ccsoo">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_5"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_GrossProfit_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" weight="-1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="10" use="optional" weight="-1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_SellingAndMarketingExpense_5" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.artemistherapeutics.com/role/InterimCondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_8"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_12"/>
<loc xlink:type="locator" xlink:href="atms-20220630.xsd#atms_CapitalReserveFromTransactionWithRelatedParties" xlink:label="loc_atms_CapitalReserveFromTransactionWithRelatedParties_12"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_13"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_14"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_16"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_18"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_18"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_18"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesNoncurrent_20"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_22"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_22"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_23"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_24"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_25"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_26"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_27"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_28"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_5" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_8" order="30" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5" xlink:to="loc_us-gaap_InventoryNet_9" order="40" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_StockholdersEquity_12" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12" xlink:to="loc_atms_CapitalReserveFromTransactionWithRelatedParties_12" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12" xlink:to="loc_us-gaap_AdditionalPaidInCapital_13" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12" xlink:to="loc_us-gaap_CommonStockValue_14" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15" order="30" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12" xlink:to="loc_us-gaap_PreferredStockValue_16" order="40" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_Liabilities_18" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_18" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_18" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_18" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_18" xlink:to="loc_us-gaap_DueToRelatedPartiesNoncurrent_20" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_18" xlink:to="loc_us-gaap_LiabilitiesCurrent_22" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_22" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22" xlink:to="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_23" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_24" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22" xlink:to="loc_us-gaap_ShortTermBorrowings_25" order="30" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_26" order="40" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_27" order="50" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_28" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.artemistherapeutics.com/role/InterimCondensedConsolidatedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
<loc xlink:type="locator" xlink:href="atms-20220630.xsd#atms_ProceedsFromRepaymentOfLoanReceivedFromStockholders" xlink:label="loc_atms_ProceedsFromRepaymentOfLoanReceivedFromStockholders_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromOtherShortTermDebt_3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_5"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_10"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_11"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_12"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_13"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_15"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_17"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="loc_atms_ProceedsFromRepaymentOfLoanReceivedFromStockholders_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_2" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="loc_us-gaap_ProceedsFromOtherShortTermDebt_3" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4" order="30" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_5" order="40" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7" order="0" use="optional" weight="-1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_9" order="0" use="optional" weight="-1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_ShareBasedCompensation_10" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_Depreciation_11" order="20" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_12" order="30" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_13" order="40" use="optional" weight="-1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="50" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_15" order="60" use="optional" weight="-1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_16" order="70" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_17" order="80" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.artemistherapeutics.com/role/INVENTORIESDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_0"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_2"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryFinishedGoods_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_2" order="10" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.artemistherapeutics.com/role/LEASESDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0" xlink:to="loc_us-gaap_OperatingLeaseCost_1" order="0" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.artemistherapeutics.com/role/LEASESDetails2">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_3"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_2" order="10" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_3" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.artemistherapeutics.com/role/IncomeTaxScheduleOfDeferredIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2" order="10" use="optional" weight="-1"/>
</calculationLink>
</linkbase>

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/21/22  Manuka, Inc.                      S-1/A                 58:6.1M                                   Z-K Global Ltd./FA

4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/09/22  Manuka, Inc.                      8-K:5,9     9/08/22   11:172K                                   Z-K Global Ltd./FA
 7/05/22  Manuka, Inc.                      8-K:1,2,3,5 6/30/22   21:2.4M                                   Z-K Global Ltd./FA
 5/23/22  Manuka, Inc.                      10-Q        3/31/22   43:2.6M                                   Z-K Global Ltd./FA
 9/24/10  Artemis Therapeutics, Inc.        8-K:5,9     9/24/10    5:52K                                    Z-K Global Ltd./FA
↑Top
Filing Submission 0001178913-22-003487   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Mon., Apr. 29, 9:54:49.1pm ET